These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 19064968)
1. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. Ferrone CR; Levine DA; Tang LH; Allen PJ; Jarnagin W; Brennan MF; Offit K; Robson ME J Clin Oncol; 2009 Jan; 27(3):433-8. PubMed ID: 19064968 [TBL] [Abstract][Full Text] [Related]
2. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Lucas AL; Shakya R; Lipsyc MD; Mitchel EB; Kumar S; Hwang C; Deng L; Devoe C; Chabot JA; Szabolcs M; Ludwig T; Chung WK; Frucht H Clin Cancer Res; 2013 Jul; 19(13):3396-403. PubMed ID: 23658460 [TBL] [Abstract][Full Text] [Related]
4. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. Hamel N; Kotar K; Foulkes WD BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239 [TBL] [Abstract][Full Text] [Related]
6. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153 [TBL] [Abstract][Full Text] [Related]
7. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Agalliu I; Gern R; Leanza S; Burk RD Clin Cancer Res; 2009 Feb; 15(3):1112-20. PubMed ID: 19188187 [TBL] [Abstract][Full Text] [Related]
8. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492 [TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756 [TBL] [Abstract][Full Text] [Related]
10. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K J Natl Cancer Inst; 1999 Dec; 91(24):2112-7. PubMed ID: 10601383 [TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347 [TBL] [Abstract][Full Text] [Related]
12. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794 [TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
14. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298 [TBL] [Abstract][Full Text] [Related]
15. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Roa BB; Boyd AA; Volcik K; Richards CS Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191 [TBL] [Abstract][Full Text] [Related]
16. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962 [TBL] [Abstract][Full Text] [Related]
17. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877 [TBL] [Abstract][Full Text] [Related]
18. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464 [TBL] [Abstract][Full Text] [Related]
19. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. Kirchhoff T; Satagopan JM; Kauff ND; Huang H; Kolachana P; Palmer C; Rapaport H; Nafa K; Ellis NA; Offit K J Natl Cancer Inst; 2004 Jan; 96(1):68-70. PubMed ID: 14709740 [TBL] [Abstract][Full Text] [Related]
20. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer. Dagan E Genet Test; 2008 Jun; 12(2):267-71. PubMed ID: 18439109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]